The Enigmatic Development of Psoriasis and Psoriasiform Lesions During Anti-TNF Therapy: A Review

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 4, 2008, Pages 251-255

  Grinblat, Beni ^a   Scheinberg, Morton ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

anti TNF agents; psoriasis; psoriatic arthritis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG WITHDRAWAL; EPIDERMIS HYPERPLASIA; FEMALE; FLEXURAL PSORIASIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MALE; MEDICAL LITERATURE; MEDLINE; NAIL DISEASE; PARAKERATOSIS; PRIORITY JOURNAL; PSORIASIFORM ERUPTION; PSORIASIS; PSORIASIS GUTATTE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUBLICATION; PUSTULOSIS; PUSTULOSIS PALMOPLANTARIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN ABSCESS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349179252     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.05.004     Document Type: Article

References (44)

1. Sany J. Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution. C R Biol 329 4 (2006) 228-240
2. Mease P. Psoriatic arthritis update. Bull Hosp Jt Dis 64 (2006) 25-31
3. Jacobi A., Mahler V., Schuler G., and Hertl M. Treatment of inflammatory dermatoses by tumor necrosis factor antagonists. J Eur Acad Dermatol Venereol 20 (2006) 1171-1187
4. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 17 295 (2006) 2275-2285
5. Thielen A.M., Kuenzli S., and Saurat J.H. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 211 (2005) 209-217
6. Grinblat B., and Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum 52 (2005) 1333-1334
7. Goncalves D.P., Laurindo I., and Scheinberg M. The appearance of pustular psoriasis during antitumor necrosis factor therapy. J Clin Rheumatol 12 (2006) 262
8. Beuthien W., Mellighoff H.U., and von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 50 (2004) 1690-1692
9. Kary S., Worm M., Fritz J., Audring H., Scherer H.U., Lee H., et al. New onset or agravation of psoriatic skin lesions in patients with definite rheumatoid arthritis under treatment with TNF-alpha antagonists: report of 8 cases. Ann Rheum Dis 63 (2004) 276
10. Haibel H., Spiller I., and Strassere C. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports. Ann Rheum Dis 63 (2004) 405
11. Baeten D., Kruithof E., Van den Bosch F., Van den Bossche N., Herssens A., Mielants H., et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?. Ann Rheum Dis 62 (2003) 829-834
12. Verea M., Del Pozo J., Yebra-Pimentel M., Porta A., and Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 38 (2004) 54-57
13. Flendrie M., Vissers W.H., Creemers M.C., Jong E.M., Van de Kerkhof P.C., and van Riel P.L. Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7 (2005) 666-676
14. Thurber M., Feasel A., Stroehlein J., and Hymes S.R. Pustular psoriasis induced by infliximab. J Drugs Dermatol 3 (2004) 439-440
15. Dereure O., Guillot B., Jorgensen C., Cohen J.D., Combes B., and Guilhou J.J. Psoriatic lesions induced by ant tumor necrosis factor alpha treatment: two cases. Br J Dermatol 151 (2004) 506-507
16. Sifkakis P.P., Iliopoulos A., Elezoglou A., Kittas C., and Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52 (2005) 2513-2518
17. Peramiquel L., Puig L., Dalmau J., Ricart E., Roe E., and Alomar A. Onset of flexural psoriasis during infliximab treatment for Crohn's Disease. Clin Exp Derm 30 (2005) 713-714
18. Michaelsson G., Kajermo U., Michaelsson A., and Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor alpha in the normal palmar eccrine sweat duct?. Br J Dermatol 153 (2005) 122-147
19. Sari I., Akar S., Birlik M., Sis B., Onen F., and Akkoc N. Anti-tumor necrosis factor alpha-induced psoriasis. J Rheumatol 33 (2006) 1411-1414
20. Pirard D., Arco D., Debrouckere V., and Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 213 (2006) 182-186
21. Peek R., Scott-Jupp R., Strike H., Clinch J., and Ramanan A.V. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 65 (2006) 1259
22. Cohen J.D., Bournerias I., Buffard V., Paufler A., Chevalier X., Bagot M., et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34 (2007) 380-385
23. Matthews C., Rogers S., and FitzGerald O. Development of new-onset psoriasis while on anti-TNF alpha treatment. Ann Rheum Dis 65 (2006) 1529-1530
24. Roux C.H., Brocq O., Leccia N., Giacchero D., Breuil V., Albert C., et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?. J Rheumatol 34 (2007) 434-437
25. Richette P., Viguier M., Bachelez H., and Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?. J Rheumatol 34 (2007) 438-439
26. Ritchlin C., and Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents. Ann Rheum Dis 65 (2006) 1541-1544
27. Skov L., and Baadsgaard O. Bacterial superantigens and inflammatory skin diseases. Clin Exp Dermatol 25 (2000) 57-61
28. Tomi N., Kranke B., and Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis and erythroderma and in healthy control subjects. J Am Acad Dermatol 53 (2005) 67-72
29. Yarwood J., Leung D., and Schlievert P. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis and Kawasaki syndrome. FEMS Microbiol Lett 192 (2000) 1-7
30. Carter J.D. Tumour necrosis factor inhibition causing psoriasis?. A more plausible explanation exists. Ann Rheum Dis 65 (2006) 1680
31. Spencer J.M., Silvers D.N., and Grossman M.E. Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption?. Br J Dermatol 130 (1994) 514-519
32. Deng A., Harvey V., Sina B., Strobel D., Badras A., Junkins-Hopkins J.M., et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 142 (2006) 198-202
33. Saissi E.H., Beau-Salinas F., Jonville-Bera A.P., Lorette G., and Autret-Leca E. Drugs associated with acute generalized exanthematic pustulosis. Ann Dermatol Venereol 130 (2003) 612-618
34. Asumalahti K., Ameen M., Suamela S., Hagforsen E., Michaelsson G., Evans J., et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120 (2003) 1667-1671
35. Banchereau J., Pascual V., and Palucka A.K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20 (2004) 539-550
36. Bennet L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematous blood. J Exp Med 197 (2003) 711-723
37. Nestle F.O., and Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interpheron alpha. J Invest Dermatol 125 (2005) xiv-xv
38. Seckin D., Durusay C., and Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 21 (2004) 577-579
39. Ladoyanni E., and Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol 4 (2005) 221-222
40. Ketikoglou I., Karatapanis S., Elefsiniotis I., Kafiri G., and Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 15 (2005) 107-109
41. Jiang H., and Chess L. Regulation of immune responses by T cells. N Engl J Med 354 (2006) 1166-1176
42. Esparza E.M., and Arch R.H. Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 174 (2005) 7869-7874
43. Lee H.H., Song I.H., Friedrich M., Gauliard A., Detert J., Rowert J., et al. Cutaneous side effects in patients with rheumatoid diseases during application of tumor necrosis factor alpha antagonists. Br J Dermatol 156 (2007) 486-491
44. Massara A., Cavazzini P., and Trotta F. In SAPHO syndrome anti TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45 (2006) 730-733